Harper Investing’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q1
Sell
-2,822
Closed -$234K 43
2022
Q4
$234K Sell
2,822
-4,317
-60% -$350K 0.29% 39
2022
Q3
$540K Buy
7,139
+261
+4% +$22K 0.55% 33
2022
Q2
$511K Buy
6,878
+2,222
+48% +$167K 0.52% 41
2022
Q1
$418K Buy
+4,656
New +$430K 0.39% 44

Other funds holding XBI

Harper Investing's XBI Position: Q1 2023 in Review

Harper Investing sold out of State Street SPDR S&P Biotech ETF (XBI) in Q1 2023, closing a stake of 2,822 shares — an estimated $234K sold.

Harper Investing first reported a position in XBI in Q1 2022 and held it in 4 quarters. The position peaked at $540K in Q3 2022. 712 funds tracked by Wall St. Rank hold XBI as of Q1 2023.

  • Harper Investing reported no remaining State Street SPDR S&P Biotech ETF position as of Q1 2023 after selling out during the quarter.
  • Harper Investing sold 2,822 State Street SPDR S&P Biotech ETF shares in Q1 2023, an estimated $234K.
  • Harper Investing first reported a position in State Street SPDR S&P Biotech ETF in Q1 2022 and held it in 4 quarters.
  • Harper Investing's State Street SPDR S&P Biotech ETF position peaked at $540K in Q3 2022.
  • 712 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q1 2023.

Based on Harper Investing's 13F filing for Q1 2023, filed 26 Apr 2023.